SynthesisObesity reviews : an official journal of the International Association for the Study of Obesity2026
The Role of Fat-Free Mass in Weight-Related Complications: A Rapid Review and Meta-Analysis.
Synthesis in Obesity reviews : an official journal of the International Association for the Study of Obesity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis review synthesized evidence on the association between fat-free mass (FFM) metrics and weight-related metabolic complications in adults with overweight or obesity.
methodsA systematic search of Medline, Embase, Web of Science, and Google Scholar (inception to October 2024) identified 32 observational studies involving 138,935 participants. Random-effects meta-analyses were conducted for type 2 diabetes (T2DM, 5 studies, n = 41,235), metabolic syndrome (MetS, 3 studies, n = 2832), cardiovascular disease (CVD, 3 studies, n = 8980), and non-alcoholic fatty liver disease (NAFLD, 3 studies, n = 4570). Heterogeneity was assessed using I
resultsLow FFM metrics were significantly associated with increased risk of T2DM (pooled RR = 1.46, 95% CI 1.11-1.91), MetS (OR = 4.48, 95% CI 2.18-9.22), CVD (RR = 2.03, 95% CI 1.27-3.26), and NAFLD (RR = 2.24, 95% CI 1.52-3.32). High heterogeneity was observed for T2DM (I
conclusionsLow FFM-related metrics were associated with increased risk of major weight-related metabolic complications, although the strength and consistency of associations differed by FFM metric type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.